Expansion Phase 1 Study of Pegargiminase Plus Pemetrexed and Cisplatin in Patients With Argininosuccinate Synthetase 1–Deficient Mesothelioma: Safety, Efficacy, and Resistance Mechanisms

Expansion Phase 1 Study of Pegargiminase Plus Pemetrexed and Cisplatin in Patients With Argininosuccinate Synthetase 1–Deficient Mesothelioma: Safety, Efficacy, and Resistance Mechanisms

Introduction: Pegargiminase (ADI-PEG 20; ADI) degrades arginine and potentiates pemetrexed (Pem) cytotoxicity in argininosuccinate synthetase 1 (ASS1)–deficient malignant pleural mesothelioma (MPM). We conducted a phase 1 dose-expansion study at the recommended phase 2 dose of ADI-PEG 20 with Pem an...

Full description

Bibliographic Details
Main Authors: Peter W. Szlosarek, MD, PhD, Melissa M. Phillips, MD, PhD, Iuliia Pavlyk, PhD, Jeremy Steele, MD, Jonathan Shamash, MD, James Spicer, MD, PhD, Sanjeev Kumar, MD, Simon Pacey, MD, PhD, Xiaoxing Feng, PhD, Amanda Johnston, PhD, John Bomalaski, MD, Graeme Moir, MD, Kelvin Lau, MD, Stephen Ellis, MD, Michael Sheaff, MD
Format: Article
Language:English
Published: Elsevier 2020-11-01
Series:JTO Clinical and Research Reports
Subjects:
Arginine
ASS1
ADIPemCis
Mesothelioma
Macrophages
Online Access:http://www.sciencedirect.com/science/article/pii/S2666364320301399

Internet

http://www.sciencedirect.com/science/article/pii/S2666364320301399

Similar Items